Navigation Links
Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
Date:11/29/2007

. MT103 specifically targets the CD19 antigen, which is present on B-cells and B-cell-derived tumors, but not on other types of blood cells or healthy tissues.

Micromet and MedImmune are developing MT103 under the terms of a 2003 agreement in which MedImmune has obtained exclusive rights for the BiTE antibody in North America. Micromet has retained the rights to MT103 outside of North America.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody in Micromet's product pipeline developed utilizing the BiTE(R) antibody technology platform, is being evaluated in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of therapeutic antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, a subsidiary of Astra Zeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293, which is currently being tested in a phase 1 clinical trial, is licensed to TRACON Pharmaceuticals, Inc. and is being developed for the treat
'/>"/>

SOURCE Micromet, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Foot and Ankle ... new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region – and ... FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland ...
(Date:8/2/2015)... ... August 03, 2015 , ... Career Step, an online institution ... Association for Healthcare Documentation Integrity’s (AHDI) conference being held in Alexandria, Virginia, on ... the AHDI conference provides us to interact with those in the healthcare documentation ...
(Date:8/1/2015)... In (PRWEB) , ... August 02, 2015 , ... ... month which will help the continuity of care for patients at this natural health ... of the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our ...
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it is embarking ... The goal is to bring this Torah – dating from 1880 – back to ... religious services. , Scroll No. 515, from the town of Taus-Domazlice, is on ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, ... to download on the Apple AppStore. , The app is designed to track ... acting as a tool to view personal health and use this information for positive ...
Breaking Medicine News(10 mins):Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2
... are the top among nuts and seeds that contain ... cholesterol levels and improves heart health, according to a ... University analysed some 27 nut and seed products in ... to date, science portal EurekAlert reported. ,They found ...
... institution, Lasik, the eye surgery that corrects vision be means ... An average procedure costs somewhere between $3,000 to $5,000 and ... are still question marks over the efficacy of the treatment ... that over 18 percent of the people require a second ...
... Professor Stanley Finger of Washington University writes in his ... Benjamin Franklin who has been a great scientist, inventor, ... any formal medical education has contributed a lot to ... practicing medicine in America during the 18th Century in ...
... that being a misfit in her group kept her away from ... further insisted that perhaps her dislike of living in the fast ... she was younger. ,I missed out on the whole ... in my life. I've never taken coke, Femalefirst quoted her, as ...
... Hormone is chanted as the new anti-ageing mantra. The ... (HGH) therapy has found some positive results. // ... have something here which may be able to reverse ... from Denmark state, Replacement therapy with Growth Hormone has ...
... the Australian Nobel Prize winners for medicine received their awards ... Stockholm yesterday. // ,The Nobel Committe was ... concept. Professor Marshall and Dr Warren were of the opinion ... stress or lifestyle changes as previously believed. To prove this ...
Cached Medicine News:Health News:LASIK Treatments Still To Reach Common Man 2
(Date:7/31/2015)... 31, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... previously announced underwritten public offering of 7,666,667 shares ... price of $11.25 per share. The shares of ... issued upon the exercise in full by the ...
(Date:7/31/2015)... WOODCLIFF LAKE, N.J. and SAN ... announced today that its parent company Eisai Co., Ltd. ... Haruo Naito , "Eisai") and Halozyme Therapeutics, Inc. ... and CEO: Dr. Helen Torley , "NASDAQ: HALO") ... eribulin mesylate (brand name: Halaven ® , "eribulin") in ...
(Date:7/31/2015)... According to a new market research report ... Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air Displacement Plethysmography ... to 2019", published by MarketsandMarkets, the global Body Composition ... is estimated to grow to $1,425.7 Million by 2019, ... 2019. Browse 41 market data Tables ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... in high performance ultrasound design provides ... echocardiography. Echocardiography imaging requires superior spatial ... Doppler performance. The Terason Echo Ultrasound ... Architecture, delivers a compact imaging platform ...
... the first intra-operative fluorescent imaging system ... the location of the coronary arteries ... coronary artery bypass procedures. ,The patented ... to view, record, replay, print, and ...
... the ingestible SmartPill pH.p Capsule passes through the ... power RF carrier frequencies to the SmartPill Data ... is worn by the patient (supported by either ... records pressure, temperature and pH measurement data, and ...
... light source offers the industry standard high intensity ... at a lower price. A universal turret on ... be used with Olympus, Storz, ACMI/Circon and Wolf ... and re-settable bulb timer. The White Sun will ...
Medicine Products: